Vect-Horus has signed a research agreement with Janssen Pharmaceuticals for the development of neurodegenerative disease treatments.
Under the deal, Janssen will undertake pre-clinical and clinical development of monoclonal antibodies, while Vect-Horus will conduct conjugate designs and carry out proof-of-concept brain uptake studies.
Once the therapies are approved, Janssen will utilise Vect-Horus’ VECTrans technology to deliver its monoclonal therapeutics to patients.
Based in France, Vect-Horus is a biotechnology company focused on the design and development of peptide-based vectors, while Janssen is a Belgium-based pharmaceutical company and a subsidiary of Johnson & Johnson.
Amgen has partnered with Magellan Rx Management to enhance care for chronic illness patients.
The two companies will initially focus on enhancing the treatment outcomes in migraine and osteoporosis patients, including improving disease management following a bone fracture.
Magellan Rx will be responsible for educating both patients and healthcare providers on handling fractures and treatment. It will also work on migraine management aspects, including costs, gaps, and patient insights.
Amgen is a biopharmaceutical company focused on the development of new medicines, while Magellan Rx is a unit of healthcare company Magellan Health.
Both companies involved in the transaction are based in the US.
Bristol-Myers Squibb has entered a partnership with Vedanta Biosciences for evaluating its drug Opdivo in combination with VE800 drug for the treatment of metastatic cancers.
The two companies intend to examine whether VE800 can improve outcomes for advanced or metastatic cancer patients in combination with Opdivo.
Vedanta will hold the rights to the VE800 programme, including research and development (R&D) and marketing rights.
Bristol-Myers is expected to make an equity investment in Vedanta Biosciences as part of the partnership, which is subject to definitive transaction agreements of the two parties.
Based in the UK, Vedanta Biosciences is a subsidiary of PureTech Health and a microbiome company, while Bristol-Myers is a biopharmaceutical company based in the US.
Novo Nordisk has signed a research collaboration agreement with E-therapeutics for the treatment of type-2 diabetes.
The companies will work for a year on E-therapeutics’ Network-Driven Drug Discovery (NDD) platform, under the agreement.
Novo Nordisk will hold an option to licence the relevant intellectual property generated and will also pay E-therapeutics for its contribution.
Based in Denmark, Novo Nordisk is pharmaceutical company engaged in diabetes care, while E-therapeutics is a UK-based pharmaceutical company focused on the discovery of treatments for cancer and degenerative diseases of the nervous system.
Global Antibiotic Research and Development Partnership (GARDP) has entered a partnership with Eisai and Takeda Pharmaceutical to discover new antibiotics.
Eisai and Takeda will allow GARDP to access and screen its components in their chemical libraries. Institut Pasteur Korea will also test both libraries for compounds with potential antibacterial activity.
Eisai and Takeda are pharmaceutical companies based in Japan, while GARDP is a joint venture (JV) between Drugs for Neglected Diseases Initiative (DNDi) and the World Health Organization (WHO), which is engaged in developing new treatments for bacterial infections.